The incidence of inflammatory bowel disease, or IBD, has rapidly increased — especially among children. In this test-specific episode of the "Answers From the Lab" podcast, Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' gene sequencing panel (Test ID: EOIBD) comprehensively evaluates patients with suspected monogenic early onset IBD.

"The results can be game changers for these patients," Dr. Moyer says. "Testing can not only help establish the diagnosis but also guide therapy."

Monogenic IBD is caused by variance in a single gene. Mayo Clinic Laboratories' test panel covers 107 genes. It's designed to provide greater accuracy than alternative options, such as functional testing, or exome or genome sequencing.

"Our specialized team includes laboratory technologists, genetic counselors, and laboratory directors, who work together to interpret the results for each patient tested," Dr. Moyer says.

Listen to learn more about Mayo Clinic Laboratories' EOIBD test panel.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

EOIBD   | Early Onset Monogenic Inflammatory Bowel Disease (IBD) Gene Panel, Varies

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less